JPWO2023282281A1 - - Google Patents

Info

Publication number
JPWO2023282281A1
JPWO2023282281A1 JP2023533162A JP2023533162A JPWO2023282281A1 JP WO2023282281 A1 JPWO2023282281 A1 JP WO2023282281A1 JP 2023533162 A JP2023533162 A JP 2023533162A JP 2023533162 A JP2023533162 A JP 2023533162A JP WO2023282281 A1 JPWO2023282281 A1 JP WO2023282281A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023533162A
Other languages
Japanese (ja)
Other versions
JP7687637B2 (ja
JPWO2023282281A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023282281A1 publication Critical patent/JPWO2023282281A1/ja
Publication of JPWO2023282281A5 publication Critical patent/JPWO2023282281A5/ja
Application granted granted Critical
Publication of JP7687637B2 publication Critical patent/JP7687637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023533162A 2021-07-07 2022-07-06 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法 Active JP7687637B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2021113006 2021-07-07
JP2021113006 2021-07-07
JP2021145370 2021-09-07
JP2021145370 2021-09-07
JP2022103949 2022-06-28
JP2022103949 2022-06-28
PCT/JP2022/026804 WO2023282281A1 (ja) 2021-07-07 2022-07-06 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法

Publications (3)

Publication Number Publication Date
JPWO2023282281A1 true JPWO2023282281A1 (https=) 2023-01-12
JPWO2023282281A5 JPWO2023282281A5 (https=) 2024-03-18
JP7687637B2 JP7687637B2 (ja) 2025-06-03

Family

ID=84801690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533162A Active JP7687637B2 (ja) 2021-07-07 2022-07-06 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法

Country Status (5)

Country Link
US (1) US20240309059A1 (https=)
EP (1) EP4368631A4 (https=)
JP (1) JP7687637B2 (https=)
TW (1) TW202317599A (https=)
WO (1) WO2023282281A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026068449A1 (en) * 2024-09-24 2026-04-02 Universite De Geneve Antibody- like binding molecules and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106559844B (zh) 2015-09-25 2020-03-24 电信科学技术研究院 一种上行传输资源调度及上行传输方法、装置
JP6974512B2 (ja) 2020-01-21 2021-12-01 本田技研工業株式会社 車両のフロア構造
KR20230017215A (ko) * 2020-05-27 2023-02-03 유니버시티 오브 워싱턴 드 노보 설계한 단백질 스위치에 기반한 모듈형의 일반화 가능한 바이오센서 플랫폼
EP4182027A1 (en) * 2020-07-14 2023-05-24 University of Washington Sars-cov-2 inhibitors
JP2022103949A (ja) 2020-12-28 2022-07-08 セイコーエプソン株式会社 インクセット及び記録方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIBILASHVILI, R., ET AL., BIOMED KHIM, vol. Vol. 67, Issue 3, JPN6022037208, 2021, pages 244 - 250, ISSN: 0005438821 *
CAMPOS, L., ET AL., J PHYS CHEM B, vol. Vol. 125, Issue 24, JPN6022037211, 2021, pages 6572 - 6586, ISSN: 0005438824 *
CAO, L., ET AL.: "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors", SCIENCE, vol. Vol. 370, Issue 6515, JPN6022037212, 2020, pages 426 - 431, XP055808389, ISSN: 0005438819, DOI: 10.1126/science.abd9909 *
CHOWDHURY, S., ET AL.: "Antiviral Peptides as Promising Therapeutics against SARS-CoV-2", J PHYS CHEM, vol. Vol. 124, Issue 44, JPN6022037209, 2020, pages 9785 - 9792, ISSN: 0005438822 *
HAN, Y., ET AL.: "Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2", ACS NANO, vol. 14, JPN6022037207, 2020, pages 5143 - 5147, XP055732485, ISSN: 0005438820, DOI: 10.1021/acsnano.0c02857 *
SITTHIYOTHA, T., ET AL., J PHYS CHEM B, vol. Vol. 124, Issue 48, JPN6022037210, 2020, pages 10930 - 10942, ISSN: 0005438823 *

Also Published As

Publication number Publication date
EP4368631A4 (en) 2025-08-13
JP7687637B2 (ja) 2025-06-03
WO2023282281A1 (ja) 2023-01-12
EP4368631A1 (en) 2024-05-15
US20240309059A1 (en) 2024-09-19
TW202317599A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023542453A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231213

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20241011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250514

R150 Certificate of patent or registration of utility model

Ref document number: 7687637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150